Remimazolam in intensive care unit: Potential applications and considerations

Area of Science:

• Pharmacology
• Critical Care Medicine

Background:

• Current sedatives and anesthetics in intensive care units (ICUs) have limitations.
• There is a need for safer and effective sedation options for critically ill patients.

Purpose of the Study:

• To explore the potential use of Remimazolam in the ICU and critical care settings.
• To evaluate its pharmacological characteristics, clinical applications, and comparative effectiveness.

Main Methods:

• Literature review of PubMed and Google Scholar.
• Search terms included Remimazolam, critical care, intensive care, sedation, anesthesia, pharmacokinetics, and pharmacodynamics.
• Analysis of relevant English-language articles.

Main Results:

• Remimazolam is an ultra-short-acting benzodiazepine derivative with potential for sedation and anesthesia.
• It presents a safer option for hemodynamically unstable, elderly, or patients with hepatic or renal impairment.
• Demonstrates comparable deep sedation to propofol, reduces post-procedural delirium, enhances patient comfort, and decreases sedative needs in pediatrics.

Conclusions:

• Remimazolam is a viable alternative to current ICU sedatives and anesthetics with comparable costs.
• Further research is needed on its long-term safety and broader clinical integration in ICUs.